Elevated soluble C5b-9 in CSF of neuromyelit… [Scand J Immunol. 2013] – PubMed – NCBI.
Elevated soluble C5b-9 in CSF of neuromyelitis optica.
Source
Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China; Multiple Sclerosis Center, Department of Neurology, The Third Affiliated Hospital of Sun-yatsen University, Guangzhou, Guangdong Province, China.
Abstract
BACKGROUND:
Neuromyelitis optica (NMO) and multiple sclerosis (MS) are two of autoimmune inflammatory demyelinating disease in the central nervous system (CNS). Complement is thought to have an important role in pathogenesis of these diseases, especially in NMO. However, the change of terminal complement complex (TCC, C5b-9) in NMO patients is still unclear.
METHODS:
Cerebrospinal fluid (CSF) C3a, C5a, sC5b-9 were measured by enzyme-linked immunosorbent assay (ELISA) in NMO (n=26), MS (n=25), and other neurological disease patients (OND, n=19).
RESULTS:
CSF levels of C5a in NMO patients were higher than OND patients (p=0.006). Elevated CSF sC5b-9 were found in the NMO patients compared to MS patients (p=0.029), and OND patients (p=0.0001). CSF sC5b-9 in MS patients were also higher than OND patients (p=0.030). NMO patients revealed a trend to an increased disease disability with increased CSF sC5b-9 during relapse but not in MS (NMO: p=0.006, MS: p=0.097).
CONCLUSIONS:
CSF levels of sC5b-9 are increased in NMO patients and reflect the activation of complement in NMO. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Complement, multiple sclerosis, neuromyelitis optica, soluble C5b-9
- PMID:
- 24313854
- [PubMed – as supplied by publisher]